These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37525592)

  • 1. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.
    Brooks BR; Pioro EP; Sakata T; Takahashi F; Hagan M; Apple S
    Muscle Nerve; 2023 Oct; 68(4):397-403. PubMed ID: 37525592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
    Takahashi F; Takei K; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
    Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
    PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
    Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S
    Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
    Takei K; Tsuda K; Takahashi F; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
    Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
    Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
    Andrews JA; Meng L; Kulke SF; Rudnicki SA; Wolff AA; Bozik ME; Malik FI; Shefner JM
    JAMA Neurol; 2018 Jan; 75(1):58-64. PubMed ID: 29181534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Genge A; Pattee GL; Sobue G; Aoki M; Yoshino H; Couratier P; Lunetta C; Petri S; Selness D; Bidani S; Hirai M; Sakata T; Salah A; Apple S; Wamil A; Kalin A; Jackson CE
    Muscle Nerve; 2023 Feb; 67(2):124-129. PubMed ID: 36504406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
    Brooks BR; Pioro EP; Katz J; Takahashi F; Takei K; Zhang J; Apple S
    Muscle Nerve; 2022 Feb; 65(2):180-186. PubMed ID: 34816454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
    Al-Chalabi A; Chiò A; Merrill C; Oster G; Bornheimer R; Agnese W; Apple S
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):165-171. PubMed ID: 33109706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.